期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 9, 期 7, 页码 905-916出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.09.54
关键词
adjuvant chemotherapy; endometrial cancer; hormonal therapy; novel biologic agents; overall survival; paclitaxel; progression-free survival
类别
While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trials is only approximately 1 year. This review will discuss the developments of systemic therapy in recurrent endometrial cancer, focusing on North American trials, in particular those documenting recent progress in new drug developments, as well as the future of individualized treatment regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据